Cubist Pharmaceuticals

Patent cliffs & loss of exclusivity

A biopharmaceutical company developing and commercializing pharmaceutical products

Company

AngelList URLhttps://angel.co/cubist-pharmaceuticals
CAGE Code3U1Z5
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/cubist-pharmaceuticals
Full Address65 Hayden Avenue, Lexington, MA 02421, US
LinkedIn URLhttp://www.linkedin.com/company/cubist-pharmaceuticals
Pitchbook URLhttps://pitchbook.com/profiles/company/41218-57
Public/PrivatePublic

8 upcoming patent cliffs

DrugIngredientTypeCliff
  1. DIFICIDFIDAXOMICINSmall mol.Jan 2028
  2. CUBICINDAPTOMYCINSmall mol.Sep 2028
  3. ENTEREGALVIMOPANSmall mol.Feb 2030
  4. CUBICIN RFDAPTOMYCINSmall mol.Nov 2030
  5. SIVEXTROTEDIZOLID PHOSPHATESmall mol.Dec 2030
  6. SIVEXTROTEDIZOLID PHOSPHATESmall mol.Dec 2030
  7. DIFICIDFIDAXOMICINSmall mol.Nov 2034
  8. ZERBAXACEFTOLOZANE SULFATE; TAZOBACTAM SODIUMSmall mol.Feb 2036
  9. CUBICINDAPTOMYCINSmall mol.—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.